Literature DB >> 23411901

Dramatic resolution of choroidal neovascular abnormalities after single aflibercept injection following years of ranibizumab use.

Voraporn Chaikitmongkol1, Neil M Bressler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23411901     DOI： 10.1001/jamaophthalmol.2013.1733

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN： 2168-6165            Impact factor:   7.389


× No keyword cloud information.
  7 in total

1.  Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).

Authors:  Clement K Chan; Atul Jain; Srinivas Sadda; Neeta Varshney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

2.  Resolution of persistent pigment epithelial detachment secondary to polypoidal choroidal vasculopathy in response to Aflibercept.

Authors:  C M G Cheung; A Mohla; T Y Wong
Journal:  Eye (Lond)       Date:  2014-05-16       Impact factor: 3.775

3.  Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results.

Authors:  D S Grewal; M K Gill; D Sarezky; A T Lyon; R G Mirza
Journal:  Eye (Lond)       Date:  2014-05-16       Impact factor: 3.775

Review 4.  Polypoidal Choroidal Vasculopathy in Asians.

Authors:  Chee Wai Wong; Tien Y Wong; Chui Ming Gemmy Cheung
Journal:  J Clin Med       Date:  2015-04-24       Impact factor: 4.241

5.  Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study.

Authors:  J Cui; D Sun; H Lu; R Dai; L Xing; H Dong; L Wang; D Wei; B Jiang; Y Jiao; M M Jablonski; S Charles; W Gu; H Chen
Journal:  Eye (Lond)       Date:  2017-09-22       Impact factor: 3.775

6.  Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.

Authors:  Mohamed A Hamid; Nizar S Abdelfattah; Jamshid Salamzadeh; Sahar T A Abdelaziz; Ahmed M Sabry; Khaled M Mourad; Azza A Shehab; Baruch D Kuppermann
Journal:  Int J Retina Vitreous       Date:  2021-04-01

Review 7.  Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema.

Authors:  Angie H C Fong; Timothy Y Y Lai
Journal:  Clin Interv Aging       Date:  2013-04-29       Impact factor: 4.458
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.